Metabolic Associated Fatty Liver Disease, Pancreatic Steatosis, Obese, Lean, Chronic Hepatitis B
Conditions
Brief summary
This study aimed to evaluate the prevalence of metabolic associated fatty liver disease (MAFLD), fatty pancreas and hepatic fibrosis in obese and lean patients with chronic hepatitis B; either treatment naive or on treatment with first-line nucleos(t)ide analogs.
Detailed description
Hepatitis B virus (HBV) infection is one of the major etiologies of chronic liver disease. Pathologies caused by HBV infection range from chronic hepatitis, fibrosis, cirrhosis, to hepatocellular carcinoma (HCC). Obesity is another significant health burden. Abdominal obesity is a type of obesity that is commonly associated with severe metabolic disorders and cardiovascular diseases. Previous research has linked abdominal obesity to non-alcoholic fatty liver disease (NAFLD), insulin resistance, type 2 diabetes mellitus (T2DM), and even metabolic syndrome. In 2020, NAFLD was renamed metabolic-associated fatty liver disease (MAFLD) by a group of experts. MAFLD is defined by the presence of liver steatosis in addition to overweight/obesity, type 2 diabetes mellitus (T2DM), or metabolic dysregulation with at least two risk factors, such as an increased waist circumference, pre-diabetes, hypertension, hypertriglyceridemia, and low serum high-density lipoprotein (HDL)-cholesterol levels.
Interventions
DEVICEAbdominal Ultrasound
Standard abdominal ultrasonography performed to evaluate pancreatic steatosis by comparing pancreatic echogenicity to liver and kidney tissue.
DEVICETransient elastography
Non-invasive transient elastography used to assess hepatic steatosis and liver stiffness in patients with chronic hepatitis B.
DIAGNOSTIC_TESTWaist Circumference
The midpoint between the superior aspect of the iliac crests and the lower lateral margins of the ribs using an inelastic tape (TBW Import Ltd) that was 0.5 cm in width and 200 cm in length, according to World Health Organization (WHO) recommendations. Abdominal obesity, determined as a waist circumference of ≥94 cm in males or ≥80 cm in females according to the recommendations of the International Diabetes Federation group
DIAGNOSTIC_TESTBody mass index
It was calculated by the equation dividing the weight in kilograms by height in meters squared. BMI=〖mass〗\_kg/(〖height〗\_m\^2 )
Sponsors
Tanta University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 years or older. * Both sexes. * Chronic hepatitis B patients.
Exclusion criteria
* Hepatitis C virus (HCV) antibody positive. * Hepatocellular carcinoma (HCC). * Human immunodeficiency viruses (HIV). * Pregnancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of hepatic steatosis | Immediately post-procedure (Up to 1 hour) | Frequency of hepatic steatosis (HS) were determined via transient elastography. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Presence of pancreatic steatosis | Immediately post-procedure (Up to 1 hour) | Presence of pancreatic steatosis was evaluated via ultrasonography. |
Countries
Egypt
Outcome results
None listed